Stefan Russmann

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Rivaroxaban postmarketing risk of liver injury
    Stefan Russmann
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland Zürich Center for Integrative Human Physiology ZIHP, University of Zurich, Zurich, Switzerland Electronic address
    J Hepatol 61:293-300. 2014
  2. pmc Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP
    Anne Haeberle
    Department of Psychiatry, Ludwig Maximilian University, Munich, Germany, Nussbaumstr, 7, Munich, 80336, Germany
    BMC Psychiatry 12:153. 2012
  3. pmc Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation
    Florian Bihl
    Department of Gastroenterology and Hepatology, University Hospital of Geneva, Switzerland
    BMC Gastroenterol 10:71. 2010
  4. pmc Current concepts of mechanisms in drug-induced hepatotoxicity
    Stefan Russmann
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    Curr Med Chem 16:3041-53. 2009
  5. ncbi request reprint [Adverse reactions and risks associated with non compliance]
    Stefan Russmann
    Klinik für Klinische Pharmakologie und Toxikologie, Universitatsspital Zurich
    Ther Umsch 67:303-7. 2010
  6. doi request reprint Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients
    Olesya I Zorina
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    Pharmacoepidemiol Drug Saf 21:872-80. 2012
  7. doi request reprint Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients
    Anne B Taegtmeyer
    Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
    Swiss Med Wkly 142:w13615. 2012
  8. doi request reprint Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients
    Daniela Fritz
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Eur J Clin Pharmacol 68:1209-19. 2012
  9. doi request reprint Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients
    Olesya I Zorina
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    Drug Saf 36:247-58. 2013
  10. ncbi request reprint Medication wrong route administration: a poisons center-based study
    Alexandra Bloch-Teitelbaum
    Associated Institute of the University of Zurich, Swiss Toxicological Information Centre, Zurich, Switzerland
    Expert Opin Drug Saf 12:145-52. 2013

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Rivaroxaban postmarketing risk of liver injury
    Stefan Russmann
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland Zürich Center for Integrative Human Physiology ZIHP, University of Zurich, Zurich, Switzerland Electronic address
    J Hepatol 61:293-300. 2014
    ..Although liver injury was observed in premarketing trials of rivaroxaban, there are no published postmarketing cases of liver injury associated with rivaroxaban...
  2. pmc Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP
    Anne Haeberle
    Department of Psychiatry, Ludwig Maximilian University, Munich, Germany, Nussbaumstr, 7, Munich, 80336, Germany
    BMC Psychiatry 12:153. 2012
    ..It is largely unknown, to what extent the prescriptions in daily clinical routine correspond to these evidence based recommendations and which combinations of psychotropic drugs are frequently used...
  3. pmc Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation
    Florian Bihl
    Department of Gastroenterology and Hepatology, University Hospital of Geneva, Switzerland
    BMC Gastroenterol 10:71. 2010
    ..However, associated treatment costs for HBIG are exceedingly high...
  4. pmc Current concepts of mechanisms in drug-induced hepatotoxicity
    Stefan Russmann
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    Curr Med Chem 16:3041-53. 2009
    ..However, the complexity of interactions between genetic and environmental risk factors is considerable, and DILI therefore currently remains unpredictable for most hepatotoxins...
  5. ncbi request reprint [Adverse reactions and risks associated with non compliance]
    Stefan Russmann
    Klinik für Klinische Pharmakologie und Toxikologie, Universitatsspital Zurich
    Ther Umsch 67:303-7. 2010
    ..Computerized physician order entry and clinical decision support systems may have an additional important role for the prevention of non compliance in the future...
  6. doi request reprint Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients
    Olesya I Zorina
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    Pharmacoepidemiol Drug Saf 21:872-80. 2012
    ..The comparative evaluation of clinical decision support software (CDSS) programs regarding their sensitivity and positive predictive value for the identification of clinically relevant drug interactions...
  7. doi request reprint Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients
    Anne B Taegtmeyer
    Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
    Swiss Med Wkly 142:w13615. 2012
    ....
  8. doi request reprint Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients
    Daniela Fritz
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Eur J Clin Pharmacol 68:1209-19. 2012
    ..Clinical decision support systems (CDSS) are promoted as powerful screening tools to improve pharmacotherapy. The aim of our study was to evaluate the potential contribution of CDSS to patient management in clinical practice...
  9. doi request reprint Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients
    Olesya I Zorina
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    Drug Saf 36:247-58. 2013
    ..However, data on the comparative performance of different CDSS to detect and appropriately classify interactions in real-life prescription datasets is limited...
  10. ncbi request reprint Medication wrong route administration: a poisons center-based study
    Alexandra Bloch-Teitelbaum
    Associated Institute of the University of Zurich, Swiss Toxicological Information Centre, Zurich, Switzerland
    Expert Opin Drug Saf 12:145-52. 2013
    ..To describe clinical effects, circumstances of occurrence, management and outcomes of cases of inadvertent administration of medications by an incorrect parenteral route...
  11. doi request reprint Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification
    Thomas Frölich
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    Eur J Clin Pharmacol 67:1273-82. 2011
    ....
  12. doi request reprint Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System)
    Markus Guzek
    Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    Pharmacoepidemiol Drug Saf 20:930-8. 2011
    ..Reclassification of interactions with a focus on clinical management aimed to support the development of CDSS with higher efficacy to reduce overalerting and improve medication safety in clinical practice...
  13. doi request reprint Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection
    Monika Rau
    Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
    J Hepatol 58:669-75. 2013
    ..We aimed at studying genetic determinants of RBV kinetics, efficacy and treatment-associated anemia...
  14. ncbi request reprint Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study
    Ivana Pavik
    Institute of Physiology and Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Nephrol Dial Transplant 28:352-9. 2013
    ..FGF23 levels have been shown to increase early in chronic kidney disease (CKD); however, the corresponding soluble Klotho levels at the different CKD stages are not known...
  15. doi request reprint Phynx: an open source software solution supporting data management and web-based patient-level data review for drug safety studies in the general practice research database and other health care databases
    Marco Egbring
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091Zurich, Switzerland
    Pharmacoepidemiol Drug Saf 19:38-44. 2010
    ..To develop a software solution that supports management and clinical review of patient data from electronic medical records databases or claims databases for pharmacoepidemiological drug safety studies...
  16. doi request reprint Pharmacogenetics of drug-induced liver injury
    Stefan Russmann
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Switzerland
    Hepatology 52:748-61. 2010
    ..However, DILI is a rare complex disease, and pharmacogenetic studies have so far not been able to identify interactions of several risk factors defining a high population-attributable risk and clinically relevant absolute risk for DILI...